{
    "clinical_study": {
        "@rank": "90802", 
        "acronym": "MECHANISM-AMI", 
        "arm_group": [
            {
                "arm_group_label": "CoCr-EES, 2-week OCT follow-up", 
                "arm_group_type": "Active Comparator", 
                "description": "Undergo primary PCI with cobalt-chromium everolimus-eluting stent (CoCr-EES) for AMI culprit lesion and perform OCT observation at 2-week after PCI."
            }, 
            {
                "arm_group_label": "BMS, 2-week OCT follow up", 
                "arm_group_type": "Active Comparator", 
                "description": "Undergo primary PCI with bare metal stent (BMS) for AMI culprit lesion and perform OCT observation at 2-week after PCI."
            }, 
            {
                "arm_group_label": "CoCr-EES, 4-week OCT follow-up", 
                "arm_group_type": "Active Comparator", 
                "description": "Undergo primary PCI with cobalt-chromium everolimus-eluting stent (CoCr-EES) for AMI culprit lesion and perform OCT observation at 4-week after PCI."
            }, 
            {
                "arm_group_label": "BMS, 4-week OCT follow-up", 
                "arm_group_type": "Active Comparator", 
                "description": "Undergo primary PCI with bare metal stent (BMS) for AMI culprit lesion and perform OCT observation at 4-week after PCI."
            }
        ], 
        "brief_summary": {
            "textblock": "To evaluate early vessel response between current standard drug-eluting stent and bare-metal\n      stent in acute myocardial infarction (AMI) patients by optical coherence tomography (OCT)."
        }, 
        "brief_title": "Multicenter Randomized Comparison of Early Vascular Responses Between Everolimus-eluting Cobalt-chromium Stent and Identically Designed Bare-Metal Stent in Patients With Acute Myocardial Infarction", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Coronary Artery Disease", 
        "condition_browse": {
            "mesh_term": [
                "Coronary Artery Disease", 
                "Myocardial Ischemia", 
                "Coronary Disease", 
                "Infarction", 
                "Myocardial Infarction"
            ]
        }, 
        "detailed_description": {
            "textblock": "For primary percutaneous coronary intervention (PCI) in acute myocardial infarction (AMI)\n      patients with elevated cardiac troponin, XIENCE PRIME/Xpedition, a current standard\n      drug-eluting stent (DES), and MULTI-LINK 8, a bare-metal stent with the same design as\n      XIENCE PRIME/Xpedition, were randomly allocated in the ratio of 1:1, to compare the vessel\n      response of the stented segment by optical coherence tomography (OCT), and to clarify the\n      mechanisms of action and characteristics of these stents in AMI patients with elevated\n      cardiac troponin. OCT observation timing was also randomly allocated in 2-weeks and 4-weeks\n      after stent implantation."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  AMI definition is accordance with the third universal definition of ESC /ACCF/ AHA/\n             WHF Task Force10, detection of a rise and/or fall of cardiac biomarker values\n             [preferably cardiac troponin (cTn) I or T] with at least one value above the 99th\n             percentile upper reference limit (URL) and with at least one of the following:\n\n          -  Symptoms of ischemia.\n\n          -  New or presumed new significant ST-segment-T wave (ST-T) changes or new left bundle\n             branch block (LBBB).\n\n          -  Development of pathological Q waves in the ECG. Imaging evidence of new loss of\n             viable myocardium or new regional wall motion abnormality.\n\n          -  Identification of an intracoronary thrombus by angiography or autopsy\n\n        Exclusion Criteria:\n\n          -  Shock\n\n          -  Patients who are judged incapable of undergoing clinical follow-up 12 months after\n             PCI (Consider also the location of patients' residences)\n\n          -  Lack of specific findings of ACS by angiography (Left to the operator's decision.)\n\n          -  The culprit lesion is the left main coronary trunk\n\n          -  Lesion with the reference vascular diameter less than 2.0mm or not less than 4.5mm by\n             visual evaluation.\n\n          -  Chronic renal failure with serum creatinine level not less than 2.0mg/dl on hospital\n             visit\n\n          -  Patients on hemodialysis Cancer patients whose vital prognosis is expected to be\n             within 2 years. Surgery that requires discontinuation of the antiplatelet agent is\n             scheduled within 3 months\n\n          -  Patients who experienced adverse reaction to aspirin or clopidogrel (this shall not\n             apply for patients in whom safety of ticlopidine is confirmed)\n\n          -  Patients who took warfarin before the onset\n\n          -  Patients under 20 years old\n\n          -  Pregnant women\n\n          -  AMI due to stent thrombosis at prior stented segment."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "180", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02014753", 
            "org_study_id": "MECHANISM-AMI"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "CoCr-EES, 2-week OCT follow-up", 
                    "CoCr-EES, 4-week OCT follow-up"
                ], 
                "intervention_name": "cobalt-chromium everolimus-eluting stent (CoCr-EES)", 
                "intervention_type": "Device", 
                "other_name": [
                    "XIENCE PRIME", 
                    "XIENCE Xpedition"
                ]
            }, 
            {
                "arm_group_label": [
                    "BMS, 2-week OCT follow up", 
                    "BMS, 4-week OCT follow-up"
                ], 
                "intervention_name": "bare metal stent (BMS)", 
                "intervention_type": "Device", 
                "other_name": "MULTI-LINK 8"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Chromium", 
                "Cobalt", 
                "Everolimus", 
                "Sirolimus"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "AMI", 
            "STEMI", 
            "ACS"
        ], 
        "lastchanged_date": "December 18, 2013", 
        "location": {
            "contact": {
                "last_name": "Yoshihiro Morino, Professor"
            }, 
            "facility": {
                "address": {
                    "city": "Morioka", 
                    "country": "Japan", 
                    "zip": "020-8505"
                }, 
                "name": "Iwate Medical University Hospital"
            }, 
            "investigator": {
                "last_name": "Yoshihiro Morino, Professor", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "4", 
        "official_title": "Multicenter Randomized Comparison of Early Vascular Responses Between Everolimus-eluting Cobalt-CHromium Stent ANd Identically DeSigned Bare-Metal Stent in Patients With Acute Myocardial Infarction: MECHANISM-AMI", 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Japan: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The percentage of stent strut coverage at 4-week is primary intended to verify the \"temporal course\"", 
            "measure": "Primary endpoint: The percentage of stent strut coverage by OCT at 2-week (The percentage of stent strut coverage at 4-week is primary intended to verify the \"temporal course\" ) The percentage of stent strut coverage by OCT", 
            "safety_issue": "Yes", 
            "time_frame": "2-week"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02014753"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Iwate Medical University", 
            "investigator_full_name": "Yoshihiro Morino", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "All-cause Death, Cardiac death, Myocardial Infarction (MI), Stroke, Major bleeding", 
                "safety_issue": "Yes", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "Any Target Lesion Revascularization (TLR)", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "Clinically-driven TLR", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "Any Target Vessel Revascularization (TVR)", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "Coronary-artery bypass surgery (CABG)", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "Any revascularization", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "Angiographic binary restenosis", 
                "safety_issue": "No", 
                "time_frame": "8 month"
            }, 
            {
                "description": "Composite of All-cause death, any MI including non-target territory, any repeat revascularization and Stroke", 
                "measure": "Patient-oriented composite", 
                "safety_issue": "Yes", 
                "time_frame": "1 year"
            }, 
            {
                "description": "The percentage of stent strut malapposition\nThe presence of Intra-stent thrombus\nIntra-stent thrombus area (Maximum site)\nIntra-stent thrombus length\nThe number of Intra-stent thrombus", 
                "measure": "OCT Endpoint", 
                "safety_issue": "No", 
                "time_frame": "2-weeks and 4-weeks"
            }, 
            {
                "description": "In-segment late loss\nMinimal lumen diameter (MLD), reference vessel diameter (RVD), percent diameter stenosis (%DS)\nIn-stent late loss\nBinary restenosis (In-stent, In-segment, Peri-stent)\nAngiographically detected stent fracture\uff08based on Popma's classification \uff09\nThe number of Intra-stent thrombus", 
                "measure": "Angiographic Quantitative analysis", 
                "safety_issue": "No", 
                "time_frame": "10\u00b12 months"
            }, 
            {
                "description": "Peri-stent contrast stain (PSS)\nSite and pattern of restenosis (based on Mehran classification)", 
                "measure": "Angiographic Qualitative analysis", 
                "safety_issue": "No", 
                "time_frame": "10\u00b12 months"
            }
        ], 
        "source": "Iwate Medical University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Iwate Medical University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}